IA
ACHN

IFP Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

IFP Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-519
Closed -$1K – 3801
2018
Q4 		$1K Sell
519
-100
-16% -$283 ﹤0.01% 3463
2018
Q3 		$2K Hold
619
– – ﹤0.01% 3624
2018
Q2 		$2K Buy
619
+519
+519% +$1.77K ﹤0.01% 3673
2018
Q1 		$0 Hold
100
– – ﹤0.01% 3886
2017
Q4 		$0 Sell
100
-530
-84% -$1.93K ﹤0.01% 4250
2017
Q3 		$3K Sell
630
-8,660
-93% -$38.5K ﹤0.01% 3679
2017
Q2 		$43K Buy
9,290
+8,660
+1,375% +$34.8K ﹤0.01% 2077
2017
Q1 		$3K Hold
630
– – ﹤0.01% 3588
2016
Q4 		$3K Buy
630
+100
+19% +$532 ﹤0.01% 3576
2016
Q3 		$4K Hold
530
– – ﹤0.01% 3388
2016
Q2 		$4K Buy
+530
New +$4.55K ﹤0.01% 3296
2016
Q1 		– Sell
-330
Closed -$4K – 3790
2015
Q4 		$4K Buy
+330
New +$3K ﹤0.01% 3125

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IFP Advisors's ACHN Position: Q1 2019 in Review

IFP Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 519 shares — an estimated $1K sold.

IFP Advisors first reported a position in ACHN in Q4 2015 and held it in 12 quarters. The position peaked at $43K in Q2 2017. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

  • IFP Advisors reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • IFP Advisors sold 519 Achillion Pharmaceuticals shares in Q1 2019, an estimated $1K.
  • IFP Advisors first reported a position in Achillion Pharmaceuticals in Q4 2015 and held it in 12 quarters.
  • IFP Advisors's Achillion Pharmaceuticals position peaked at $43K in Q2 2017.
  • 110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on IFP Advisors's 13F filing for Q1 2019, filed 15 May 2019.